EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy

Rukiye Arıkan iD, Özlem Demircioğlu iD, Salih Özgüven iD, Nazım Can Demircan iD, Özkan Alan iD, Tuğba Akın Telli iD, Selver Işık iD, Tuğba Başoğlu iD, Abdussamed Çelebi iD, Alper Yaşar iD, Ceren Özge Şahin iD, Özlem Ercelep iD und 3 weitere

Indian Journal of Cancer · 2024

DOI: 10.4103/ijc.ijc_649_21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cancer, 2024. Verfasst von Rukiye Arıkan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Psoas Muscles, Kidney Neoplasms, Vascular Endothelial Growth Factor A. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Methods

This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI.

Results

Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51–66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9–9.03) months and median OS was 17 (95% CI: 10.6–23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong ( r s = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS ( P < 0.05 each). In multivariate analyses for OS, while IMDC score ( P < 0.001) and PMI ( P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score ( P < 0.001) and SMI ( P = 0.01) were significant independent prognostic factors according to multivariate analysis-2.

Conclusions

Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellPsoas MusclesKidney NeoplasmsVascular Endothelial Growth Factor ASarcopeniaHumansMaleFemaleMiddle AgedPrognosisAgedRetrospective StudiesNeoplasm Metastasis

Substanzen

Vascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey.
  • Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Division of Medical Oncology, Tekirdag State Hospital, Tekirdag, Turkey.
  • Department of Internal Medicine, Division of Medical Oncology, Acıbadem University School of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Division of Medical Oncology, Koc University School of Medicine, Istanbul, Turkey.

ORCID-Profile: Rukiye Arıkan, Özlem Demircioğlu, Salih Özgüven, Nazım Can Demircan, Özkan Alan, Tuğba Akın Telli, Selver Işık, Tuğba Başoğlu, Abdussamed Çelebi, Alper Yaşar, Ceren Özge Şahin, Özlem Ercelep, Canan Cimşit

Zitieren

APA

Arıkan, R., Demircioğlu, Ö., Özgüven, S., Demircan, N. C., Alan, Ö., Telli, T. A., Işık, S., Başoğlu, T., Çelebi, A., Yaşar, A., Şahin, C. Ö., Ercelep, Ö., Dane, F., Cimşit, C., & Yumuk, P. F. (2024). Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_649_21

Vancouver

Arıkan R, Demircioğlu Ö, Özgüven S, Demircan NC, Alan Ö, Telli TA, et al. Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy. Indian Journal of Cancer. 2024. doi:10.4103/ijc.ijc_649_21

BibTeX
@article{Arkan2024,
  author = {Arıkan, Rukiye and Demircioğlu, Özlem and Özgüven, Salih and Demircan, Nazım Can and Alan, Özkan and Telli, Tuğba Akın and Işık, Selver and Başoğlu, Tuğba and Çelebi, Abdussamed and Yaşar, Alper and Şahin, Ceren Özge and Ercelep, Özlem and Dane, Faysal and Cimşit, Canan and Yumuk, Perran Fulden},
  title = {Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy},
  journal = {Indian Journal of Cancer},
  year = {2024},
  doi = {10.4103/ijc.ijc_649_21}
}
Kostenlos starten →